Back to top
more

Quest Diagnostics (DGX)

(Real Time Quote from BATS)

$176.54 USD

176.54
262,035

+2.27 (1.30%)

Updated Aug 8, 2025 01:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (58 out of 244)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Molina Healthcare (MOH) to Get New Medicaid Contract in Iowa

by Zacks Equity Research

Molina Healthcare's (MOH) Iowa health plan is likely to commence on Jul 1 next year.

Zacks Equity Research

Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Encompass (EHC) Opens Its 4th Inpatient Rehab Unit in Illinois

by Zacks Equity Research

Encompass Health's (EHC) Quad Cities Rehabilitation Institute has 40 beds and serves patients who are recovering from enervating and complex illnesses and injuries.

Zacks Equity Research

Quest Diagnostics' (DGX) Base Volume Revives, New Ruling Aids

by Zacks Equity Research

With a bullish expectation for the remainder of 2022, Quest Diagnostics (DGX) raises its full-year guidance.

Zacks Equity Research

Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View

by Zacks Equity Research

Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.

Zacks Equity Research

National Vision (EYE) Q2 Earnings Top Mark, Revenue View Cut

by Zacks Equity Research

National Vision (EYE) is simultaneously facing demand headwinds across its network of stores, given the current macro environment, as well as supply challenges.

Zacks Equity Research

ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.

Zacks Equity Research

STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays

by Zacks Equity Research

Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.

Zacks Equity Research

Accuray (ARAY) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Despite solid Product revenues, Accuray (ARAY) reports an overall soft Q4 performance.

Zacks Equity Research

Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered

by Zacks Equity Research

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.

Zacks Equity Research

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

Zacks Equity Research

Is Quest Diagnostics (DGX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut

by Zacks Equity Research

SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.

Zacks Equity Research

Masimo's (MASI) Q2 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Masimo's (MASI) robust product shipments and strength in its healthcare business drive its Q2 sales.

Zacks Equity Research

Avanos (AVNS) Q2 Earnings Top Estimates, FY22 View Lowered

by Zacks Equity Research

Avanos's (AVNS) second-quarter 2022 results reflect strength in the Pain Management segment.

Zacks Equity Research

Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up

by Zacks Equity Research

Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.

Zacks Equity Research

Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth

by Zacks Equity Research

Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.

Zacks Equity Research

OPKO Health (OPK) Stock Gains 2.1% Despite Q2 Earnings Miss

by Zacks Equity Research

OPKO Health's (OPK) second-quarter results benefit from continued strength in its Pharmaceuticals segment.

Zacks Equity Research

NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.

Zacks Equity Research

Inogen (INGN) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Inogen's (INGN) second-quarter results benefit from higher revenues in its international business-to-business sales channel.

Zacks Equity Research

Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.

Zacks Equity Research

Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark

by Zacks Equity Research

According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.

Zacks Equity Research

Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.

Zacks Equity Research

QuidelOrtho (QDEL) Q2 Earnings Miss, Provides FY22 View

by Zacks Equity Research

QuidelOrtho's (QDEL) robust performance across majority of its business units and geographies drives its second-quarter 2022 top line.